#breast cancer — Monday, August 31, 2026 (2 items)
| 0 | ℹ |
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015).
(nature.com)
|
Nature Communications 2026-08-31 | #breast cancer #clinical trial #neoadjuvant #her2 #immunotherapy | |
| 0 | ℹ |
ERalpha Micromap (microMap) proximity labeling reveals fulvestrant mechanisms.
(nature.com)
|
Nature Communications 2026-08-31 | #breast cancer #proximity labeling #estrogen receptor #protein-interactions #drug-mechanism |